Our molecular analysis showed that of the nine genes that differentiated breast cancer biopsy specimens, regardless of the subtype from controls, only ADA and SLC23A2 expression was silenced in the tumor samples. This evidence concerns the gene SLC23A2 and breast carcinoma.